BioMarin completes rolling NDA for Duchenne drug drisapersen
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical has completed its rolling new drug application (NDA) seeking approval from the FDA for drisapersen as a treatment for patients with the rare disease disorder Duchenne muscular dystrophy (DMD).